23-epi-26-Deoxyactein
CAS No. 264624-38-6
23-epi-26-Deoxyactein ( 27-Deoxyactein )
Catalog No. M24175 CAS No. 264624-38-6
23-epi-26-Deoxyactein has anti-inflammatory activity, it inhibits nitric oxide production by reducing iNOS expression without affecting activity of the enzyme. It also has anti-cancer activity, it can inhibit growth of the MCF7 human breast cancer cells and induce cell cycle arrest at G1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 300 | In Stock |
|
10MG | 511 | In Stock |
|
25MG | 807 | In Stock |
|
50MG | 1062 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product Name23-epi-26-Deoxyactein
-
NoteResearch use only, not for human use.
-
Brief Description23-epi-26-Deoxyactein has anti-inflammatory activity, it inhibits nitric oxide production by reducing iNOS expression without affecting activity of the enzyme. It also has anti-cancer activity, it can inhibit growth of the MCF7 human breast cancer cells and induce cell cycle arrest at G1.
-
Description23-epi-26-Deoxyactein has anti-inflammatory activity, it inhibits nitric oxide production by reducing iNOS expression without affecting activity of the enzyme. It also has anti-cancer activity, it can inhibit growth of the MCF7 human breast cancer cells and induce cell cycle arrest at G1.
-
Synonyms27-Deoxyactein
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK;NO Synthase;NOS
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number264624-38-6
-
Formula Weight660.8
-
Molecular FormulaC37H56O10
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@H](C[C@]1(OC[C@@]2(C)O[C@@H]12)O[C@H]1C2)[C@@H]1[C@@](C)([C@@H](C1)OC(C)=O)[C@]2(C)[C@H](CC2)[C@]1(C1)[C@@]1(CC1)[C@@H]2C(C)(C)[C@H]1O[C@@H]([C@@H]([C@H]1O)O)OC[C@H]1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Growth inhibitory activity of extracts and purified components of black cohosh on human breast cancer cells.Breast Cancer Res Treat. 2004 Feb;83(3):221-31.
molnova catalog
related products
-
CDK9-IN-2
CDK9-IN-2 is a potent and selective CDK9 inhibitor with IC50 of <8 nM, example 4 in patent WO2011026917A1.
-
PF07104091
PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
-
FN-1501
FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).